Login to Your Account

ThromboGenics Signs Potential $494M Ex-U.S. Ocriplasmin Deal

By Nuala Moran
Staff Writer

Wednesday, March 21, 2012
LONDON – ThromboGenics NV is getting €75 million (US$98.4 million) up front as part of a €375 million-plus-royalties deal signed last week with leading eye care specialist Alcon Inc. for the ex-U.S. rights to ocriplasmin, providing the cash ThromboGenics needs to go it alone in commercializing the vitreous macular adhesion (VMA) treatment in the U.S.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription